- Home
- CTEV vs PHAT Comparison
CTEV vs PHAT Comparison
Compare CTEV & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTEV
- PHAT
- Stock Information
- Founded
- CTEV 1980
- PHAT 2018
- Country
- CTEV United States
- PHAT United States
- Employees
- CTEV N/A
- PHAT N/A
- Industry
- CTEV
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- CTEV
- PHAT Health Care
- Exchange
- CTEV NYSE
- PHAT Nasdaq
- Market Cap
- CTEV 295.8M
- PHAT 339.8M
- IPO Year
- CTEV N/A
- PHAT 2019
- Fundamental
- Price
- CTEV $20.08
- PHAT $4.03
- Analyst Decision
- CTEV Hold
- PHAT Strong Buy
- Analyst Count
- CTEV 1
- PHAT 5
- Target Price
- CTEV $19.00
- PHAT $22.50
- AVG Volume (30 Days)
- CTEV 78.6K
- PHAT 1.2M
- Earning Date
- CTEV 05-08-2025
- PHAT 05-08-2025
- Dividend Yield
- CTEV N/A
- PHAT N/A
- EPS Growth
- CTEV N/A
- PHAT N/A
- EPS
- CTEV N/A
- PHAT N/A
- Revenue
- CTEV $930,624,000.00
- PHAT $55,252,000.00
- Revenue This Year
- CTEV $2.18
- PHAT $202.23
- Revenue Next Year
- CTEV $3.04
- PHAT $113.81
- P/E Ratio
- CTEV N/A
- PHAT N/A
- Revenue Growth
- CTEV N/A
- PHAT 8001.47
- 52 Week Low
- CTEV $4.80
- PHAT $3.81
- 52 Week High
- CTEV $31.00
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- CTEV N/A
- PHAT 38.04
- Support Level
- CTEV N/A
- PHAT $3.81
- Resistance Level
- CTEV N/A
- PHAT $5.09
- Average True Range (ATR)
- CTEV 0.00
- PHAT 0.68
- MACD
- CTEV 0.00
- PHAT -0.10
- Stochastic Oscillator
- CTEV 0.00
- PHAT 7.72
About CTEV CLARITEV CORPORATION
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.